https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/233 2025-12-25T16:11:46Z 2025-12-25T16:11:46Z Aiob, Ala Kim, Kidong Lee, Nak Woo https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64092 2024-09-24T01:30:08Z 2023-12-01T00:00:00Z

Title: Rate of occult atypical hyperplasia or endometrial cancer in women of older age groups with nonatypical endometrial hyperplasia (KGOG 2026) Authors: Aiob, Ala; Kim, Kidong; Lee, Nak Woo Abstract: [No abstract available]

2023-12-01T00:00:00Z Shim, Seunghyuk Noh, Eunjin Lee, A. Jin Jang, E. B. Kim, Miseon Hwang, Han-sung Cho, Geum Joon https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63250 2024-07-11T11:00:23Z 2023-12-01T00:00:00Z

Title: Risk of adverse obstetric outcomes in patients with a history of endometrial cancer: A nationwide population-based cohort study Authors: Shim, Seunghyuk; Noh, Eunjin; Lee, A. Jin; Jang, E. B.; Kim, Miseon; Hwang, Han-sung; Cho, Geum Joon Abstract: Objective To evaluate adverse obstetric outcomes in women with a history of endometrial cancer (EC). Design Population-based cohort study. Setting The Korean National Health Insurance (KNHI) claims database. Population Women who gave birth between 2009 and 2016, with a history of EC prior to pregnancy. Methods The KNHI database was used to compare obstetric outcomes of women with and without a history of EC, using the ICD-10 codes. Multivariable logistic regression models were used to determine the associations between a history of EC and adverse obstetric outcomes. Main outcomes measures Adverse obstetric outcomes. Results Overall, 248 and 3 335 359 women with and without a history of EC, respectively, gave birth. When adjusted for age, primiparity and comorbidities, an increased risk of multiple gestations (odds ratio [OR] 4.925, 95% confidence interval [CI] 3.394–7.147), caesarean delivery (OR 2.005, 95% CI 1.535–2.62) and preterm birth (OR 1.941, 95% CI 1.107–3.404) was observed among women with a history of EC. We were unable to demonstrate significant differences in the risk of pre-eclampsia, gestational diabetes, vacuum delivery, placenta praevia, placenta accreta spectrum, placental abruption and postpartum haemorrhage between the groups. In the sensitivity analyses excluding multiple gestations, an increased risk of preterm birth was not observed among women with a history of EC (OR 1.276, 95% CI 0.565–2.881). Conclusions There is no convincing evidence of an increased risk of adverse obstetric outcomes among women with a history of EC. Our findings would be useful in counselling of patients with EC who are undergoing fertility-sparing treatment.

2023-12-01T00:00:00Z Lee, Jung-Yun Lee, Yong Jae Son, Joo-Hyuk Kim, Sunghoon Choi, Min Chul Suh, Dong Hoon Song, Jae-Yun Hong, Dae Gy Kim, Mi Kyung Kim, Jae-Hoon Chang, Suk-Joon https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64309 2024-07-11T12:30:38Z 2023-11-01T00:00:00Z

Title: Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy Authors: Lee, Jung-Yun; Lee, Yong Jae; Son, Joo-Hyuk; Kim, Sunghoon; Choi, Min Chul; Suh, Dong Hoon; Song, Jae-Yun; Hong, Dae Gy; Kim, Mi Kyung; Kim, Jae-Hoon; Chang, Suk-Joon Abstract: IMPORTANCE Hyperthermic intraperitoneal chemotherapy (HIPEC) followed by interval cytoreductive surgery (ICS) has shown survival benefits for patients with advanced-stage ovarian cancer. However, there is still a lack of consensus regarding the integration of HIPEC into clinical practice. OBJECTIVE To evaluate the safety and effectiveness of ICS with HIPEC compared with ICS alone in clinical practice for patients with advanced-stage ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS This prospective, multicenter, comparative effectiveness cohort study enrolled 205 patients with stage III or IV ovarian cancer who had received at least 3 cycles of neoadjuvant chemotherapy followed by ICS with HIPEC or ICS without HIPEC at 7 Korean Gynecologic Oncology Group institutions between September 1, 2017, and April 22, 2022. Nine patients were excluded because they did not meet the inclusion criteria. EXPOSURES Neoadjuvant chemotherapy followed by ICS with HIPEC or ICS without HIPEC. MAIN OUTCOMES AND MEASURES The primary end pointwas progression-free survival (PFS). Overall survival (OS) and the safety profile were the key secondary end points. RESULTS This study included 196 patients (median age, 58.0 years [range, 38-82 years]), of whom 109 underwent ICS with HIPEC and 87 underwent ICS without HIPEC. The median duration of follow-up was 28.2 months (range, 3.5-58.6 months). Disease recurrence occurred in 128 patients (65.3%), and 30 patients (15.3%) died. Interval cytoreductive surgery with HIPEC was associated with a significant improvement in median PFS compared with ICS without HIPEC (22.9 months [95% CI, 3.5-58.6 months] vs 14.2 months [95% CI, 4.0-56.2 months]; P =.005) and median OS (not reached [95% CI, 3.5 months to not reached] vs 53.0 [95% CI, 4.6-56.2 months]; P =.002). The frequency of grade 3 or 4 postoperative complications was similar in both groups (ICS with HIPEC, 3 of 109 [2.8%] vs ICS without HIPEC, 3 of 87 [3.4%]; P >.99). Among patients with recurrence, the frequency of peritoneal recurrence was lower in the ICS with HIPEC group than in the ICS without HIPEC group (21 of 64 [32.8%] vs 41 of 64 [64.1%]; P =.001). CONCLUSIONS AND RELEVANCE This study suggests that ICS in conjunction with HIPEC was associated with longer PFS and OS than ICS without HIPEC for patients with advanced-stage ovarian cancer and was not associated with higher rates of postoperative complications. The lower rate of peritoneal recurrence after HIPECmay be associated with improved OS.

2023-11-01T00:00:00Z Kong, Deqi Cho, Heeryun Hwang, Soowon Choi, Eunsaem Lee, Ah-young Choi, Ehn-Kyoung Kim, Yun-Bae Kim, Hai-Joong Hong, Sooncheol https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64040 2024-07-11T10:00:35Z 2023-10-01T00:00:00Z

Title: Bioinformatics and integrated pharmacology network to identify the therapeutic targets and potential molecular mechanism of alpha-lipoic acid on primary ovarian insufficiency Authors: Kong, Deqi; Cho, Heeryun; Hwang, Soowon; Choi, Eunsaem; Lee, Ah-young; Choi, Ehn-Kyoung; Kim, Yun-Bae; Kim, Hai-Joong; Hong, Sooncheol Abstract: Women experiencing primary ovarian insufficiency (POI) are more likely to experience infertility, and its incidence is increasing worldwide annually. Recently, the role of alpha-lipoic acid (ALA) in the treatment of POI has been reported. However, details of the potential pharmacological targets and related molecular pathways of ALA remain unclear and need to be elucidated. Thus, this study aims to elucidate the potential therapeutic target and related molecular mechanism of ALA on POI. First, the potential targets of POI and ALA-related targets were downloaded from online public databases. Subsequently, the overlapped target genes between POI and ALA were acquired, and gene ontology (GO), Kyoto encyclopedia of genes and genomes (KEGG) analysis, protein-protein interaction (PPI) networks were performed and constructed. Finally, molecular docking was performed to verify protein-to-protein effect. A total of 152 potential therapeutic targets were identified. The biological processes of the intersecting targets were mainly involved in the cellular response to peptides, response to xenobiotic stimuli, and response to peptide hormones. The highly enriched pathways were the cAMP, PI3K/AKT, estrogen, progesterone mediated oocyte maturation, and apoptosis signaling pathways. The top 10 hub targets for ALA in the treatment of POI were STAT3, STAT1, CASP3, MTOR, PTGS2, CASP8, HSP90AA1, PIK3CA, MAPK1, and ESR1. The binding between ALA and all top hub targets were verified using the molecular docking analysis. In summary, using the systematic integrated pharmacology network and bioinformatics analysis, this study illustrated that ALA participates in the treatment of POI via multiple targets and multiple pathways mechanisms.

2023-10-01T00:00:00Z